Reata Pharmaceuticals, Inc.
NEWS
Reata Pharmaceuticals was acquired by Biogen Inc. in September 2023.
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.
It was a busy week for clinical trial announcements. Here’s a look.
Bardoxolone methyl is an experimental, oral, once-a-day activator of Nrf2, a transcription factor that induces molecular pathways involved in resolving inflammation.
Last week was busy for clinical trial news. Here’s a look.
Reata announced late Monday that the second part of its Phase II MOXIe trial met the goal of modified Friedreich’s Ataxia Rating Scale after 48 weeks of treatment.
As the $63 billion acquisition of Allergan by Chicago-based AbbVie slowly churns through the Federal Trade Commission (FTC) process, the company continues to make the news. Here’s a look.
Biopharma companies strengthen their leadership and boards with these appointments.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
The Boston area, specifically Cambridge, has the highest concentration of biopharma companies in the U.S. That is followed rather closely by the San Francisco Bay Area. Many states want to encourage life science development—the return on investment can be very high, and the jobs they create are often well-paying jobs for skilled workers.
JOBS
IN THE PRESS